Elexacaftor is a medication used to treat cystic fibrosis, a genetic disorder that affects the lungs and digestive system. It is a combination of two other medications, tezacaftor and ivacaftor, and is used to treat a specific genetic mutation known as the F508del mutation. Elexacaftor works by restoring the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, which is responsible for the movement of chloride ions across cell membranes. This helps to reduce the thick mucus that builds up in the lungs and other organs, improving the symptoms of cystic fibrosis.
Elexacaftor is a medication that acts as a cystic fibrosis transmembrane conductance regulator (CFTR) corrector. It is not available by itself but is instead combined with tezacaftor and ivacaftor into a single pill called Trikafta. Trikafta is used to treat people with cystic fibrosis (CF) who have a specific genetic mutation called F508del.
Cystic fibrosis is an inherited disorder that causes thick, sticky mucus to build up in the lungs, digestive tract, and other organs. This mucus can clog the airways and make it hard to breathe. It can also block the tubes that carry enzymes from the pancreas to the intestines, making it difficult to digest food.
The F508del mutation is the most common cause of CF. It is caused by a deletion of three nucleotides in the CFTR gene. The CFTR gene is responsible for making a protein that helps regulate the flow of salt and water in and out of cells. The F508del mutation causes the CFTR protein to be misfolded, which means it cannot properly function.
Elexacaftor works by helping the CFTR protein to fold correctly. This allows the protein to be transported to the cell surface, where it can help to regulate the flow of salt and water. Tezacaftor works in a similar way, but by a different mechanism. Ivacaftor, the third medication in Trikafta, works by improving the function of CFTR proteins that are already on the cell surface.
Trikafta has been shown to be very effective in improving lung function and reducing symptoms of CF in people with the F508del mutation. It is a major breakthrough in the treatment of CF and has the potential to significantly improve the quality of life for people with this condition.
Here are some additional things to know about Elexacaftor:
- It is a relatively new medication, having been approved by the FDA in 2019.
- It is only available by prescription.
- The most common side effects of Trikafta are headache, diarrhea, and abdominal pain.
- Trikafta can interact with other medications, so it is important to tell your doctor about all of the medications you are taking before starting Trikafta.